GleamWall
中文EN

HUMA Humacyte, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1818382 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY52.5%
TTM net income YoY-156.3%
TTM EPS YoY-66.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin-475.1%
Operating margin-4,602.9%
Net margin-3,955.1%
FCF margin-3,697.0%
EBITDA margin-4,381.8%

Returns

ROE-1,423.6%
ROA-87.3%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets85.6%
Debt / equity2.04x
Current ratio3.34x
Interest coverage-10.97x

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-6.0%
Payout ratio—
Capex / revenue13.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.03M$406,000$495,000$467,000$753,000$301,000$517,000$0
Cost of revenue$1.43M$1.23M$2.04M$9.08M$260,000$213,000$147,000$0
Gross profit-$401,000-$825,000-$1.54M-$8.62M$493,000$88,000$370,000$0
R&D expense$14.10M$18.14M$19.46M$14.61M$17.27M$22.01M$15.42M$20.66M
SG&A expense$9.01M$8.03M$7.93M$7.62M$7.61M$7.81M$8.14M$7.43M
Operating income-$23.52M-$27.00M-$28.93M-$30.84M-$24.39M-$29.73M-$23.18M-$28.09M
Interest expense$2.37M$2.32M$2.27M$3.09M$2.61M$2.54M$3.00M$2.51M
Income tax$0$0$0$0$0$0$0$0
Net income-$15.54M-$36.80M-$17.62M-$24.80M-$17.51M-$37.66M$39.14M-$20.94M
EBITDA-$22.24M-$25.66M-$27.59M-$29.50M-$23.09M-$28.43M-$21.88M-$26.80M
EPS (basic)-0.06-0.16-0.09—-0.11-0.240.28—
EPS (diluted)-0.06-0.16-0.09—-0.11-0.240.28—
Weighted avg. shares (diluted)277.80M234.18M197.85M—158.31M155.44M131.76M—
Balance sheet
Cash & equivalents$64.52M$79.90M$48.54M$50.50M$19.84M$88.39M$113.20M$95.29M
Receivables$811,000$330,000$434,000$441,000$1.08M$394,000$488,000$0
Inventory$5.61M$6.99M$9.92M$13.59M$18.42M$11.07M$8.02M$0
Current assets$82.68M$92.79M$63.60M$67.80M$41.35M$51.73M$73.70M$47.86M
PP&E, net$14.88M$16.17M$17.38M$18.54M$19.86M$21.19M$22.44M$23.06M
Total assets$125.57M$138.09M$110.56M$116.37M$91.51M$138.79M$162.55M$137.87M
Current liabilities$24.76M$14.95M$16.19M$18.37M$25.58M$21.09M$20.03M$19.95M
Long-term debt$36.80M$36.32M$35.87M$35.44M———$0
Total debt$36.80M$36.32M$35.87M$35.44M———$0
Total liabilities$107.51M$106.83M$98.93M$113.26M$96.26M$134.74M$126.51M$190.54M
Shareholders' equity$18.06M$31.26M$11.62M$3.11M-$4.75M$4.05M$36.04M-$52.67M
Net debt-$27.72M-$43.58M-$12.67M-$15.05M———-$95.29M
Shares outstanding277.80M277.80M222.02M193.00M158.84M156.34M155.12M130.03M
Cash flow statement
Operating cash flow-$14.97M-$22.06M-$25.10M-$26.12M-$23.90M-$26.41M-$28.60M-$26.58M
Capital expenditure$0$104,000$175,000$39,000$49,000$568,000$228,000$63,000
Free cash flow-$14.97M-$22.16M-$25.28M-$26.16M-$23.95M-$26.98M-$28.83M-$26.64M
Investing cash flow$0-$104,000-$175,000-$39,000-$49,000-$568,000-$228,000-$63,000
Financing cash flow-$406,000$53.53M$23.32M$57.17M-$44.59M$2.17M$46.74M$51.01M
Depreciation & amortization$1.28M$1.34M$1.34M$1.34M$1.30M$1.30M$1.31M$1.28M
Stock-based compensation$2.34M$2.61M$3.17M$2.47M$2.51M$2.43M$2.49M$1.69M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.